The effect of allelic variation in aldo-keto reductase 1C2 on the in vitro metabolism of dihydrotestosterone

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 3, 2009, Pages 1032-1039

  Takahashi, Ryan H ^a   Grigliatti, Thomas A ^a   Reid, Ronald E ^a   Riggs, K Wayne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOKETOREDUCTASE 1C2; ANDROSTANOLONE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE; GENETIC VARIABILITY; IN VITRO STUDY; INSECT CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ANDROSTANE-3,17-DIOL; ANIMALS; CATALYSIS; CELL LINE; DIHYDROTESTOSTERONE; FLUORESCENT DYES; HUMANS; HYDROXYSTEROID DEHYDROGENASES; KINETICS; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; SPODOPTERA;

EID: 66749166052     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.150995     Document Type: Article

References (37)

1. Barbier O and Bélanger A (2008) Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab 22:259-270.
2. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, et al. (2004) Human prostate cancer risk factors. Cancer 101:2371-2490. (Pubitemid 39505434)
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Chouinard S, Barbier O, and Bélanger A (2007) UDP- glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem 282:33466-33474. (Pubitemid 350159554)
5. Chu LW, Reichardt JK, and Hsing AW (2008) Androgens and the molecular epidemiology of prostate cancer. Curr Opin Endocrinol Diabetes Obes 15:261-270.
6. Dufort I, Labrie F, and Luu-The V (2001) Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution. J Clin Endocrinol Metab 86:841-846. (Pubitemid 32208285)
7. Dufort I, Rheault P, Huang XF, Soucy P, and Luu-The V (1999) Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 140:568-574. (Pubitemid 29058186)
8. Hegedus DD, Pfeifer TA, Hendry J, Theilmann DA, and Grigliatti TA (1998) A series of broad host range shuttle vectors for constitutive and inducible expression of heterologous proteins in insect cell lines. Gene 207:241-249. (Pubitemid 28085355)
9. Hegedus DD, Pfeifer TA, Theilmann DA, Kennard ML, Gabathuler R, Jefferies WA, and Grigliatti TA (1999) Differences in the expression and localization of human melanotransferrin in lepidopteran and dipteran insect cell lines. Protein Expr Purif 15:296-307. (Pubitemid 29326377)
10. Hood SR, Shah G, and Jones P (1998) Expression of cytochromes P450 in a baculovirus system. Methods Mol Biol 107:203-218.
11. Ji Q, Chang L, Stanczyk FZ, Ookhtens M, Sherrod A, and Stolz A (2007) Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res 67:1361-1369. (Pubitemid 46270797)
12. Ji Q, Chang L, VanDenBerg D, Stanczyk FZ, and Stolz A (2003) Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 54:275-289. (Pubitemid 36228164)
13. Jin Y and Penning TM (2001) Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract Res Clin Endocrinol Metab 15:79-94. (Pubitemid 32544611)
14. Jin Y and Penning TM (2007) Aldo-keto reductases and bioactivation/ detoxication. Annu Rev Pharmacol Toxicol 47:263-292. (Pubitemid 46272131)
15. Karypidis AH, Olsson M, Andersson SO, Rane A, and Ekström L (2008) Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J 8:147-151.
16. Kidd IM and Emery VC (1993) The use of baculoviruses as expression vectors. Appl Biochem Biotechnol 42:137-159.
17. Luu-The V, Bélanger A, and Labrie F (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 22:207-221.
18. MacLeod SL, Nowell S, Plaxco J, and Lang NP (2000) An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 7:777-782.
19. Matsuura K, Deyashiki Y, Sato K, Ishida N, Miwa G, and Hara A (1997) Identification of amino acid residues responsible for differences in substrate specificity and inhibitor sensitivity between two human liver dihydrodiol dehydrogenase isoenzymes by site-directed mutagenesis. Biochem J 323:61-64. (Pubitemid 27153875)
20. Morimoto I, Edmiston A, and Horton R (1980) Alteration in the metabolism of dihydrotestosterone in elderly men with prostate hyperplasia. J Clin Invest 66:612-615. (Pubitemid 10053928)
21. Mostaghel EA and Nelson PS (2008) Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 22:243-258.
22. Negri-Cesi P and Motta M (1994) Androgen metabolism in the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 51:89-96. (Pubitemid 24340050)
23. Nunlist EH, Dozmorov I, Tang Y, Cowan R, Centola M, and Lin HK (2004) Partitioning of 5alpha-dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation. J Steroid Biochem Mol Biol 91:157-170. (Pubitemid 38992810)
24. Palackal NT, Lee SH, Harvey RG, Blair IA, and Penning TM (2002) Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells. J Biol Chem 277:24799-24808. (Pubitemid 34952012)
25. Park JY, Tanner JP, Sellers TA, Huang Y, Stevens CK, Dossett N, Shankar RA, Zachariah B, Heysek R, and Pow-Sang J (2007) Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 70:374-379. (Pubitemid 47362236)
26. Penning TM, Bauman DR, Jin Y, and Rizner TL (2007) Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor. Mol Cell Endocrinol 265-266:77-82. (Pubitemid 46273954)
27. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, and Ratnam K (2000) Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67-77.
28. Penning TM and Drury JE (2007) Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys 464:241-250. (Pubitemid 47214569)
29. Penning TM, Jin Y, Rizner TL, and Bauman DR (2008) Pre-receptor regulation of the androgen receptor. Mol Cell Endocrinol 281:1-8. (Pubitemid 350296604)
30. Reddy DS (2004) Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol. Neuroscience 129:195-207. (Pubitemid 39360955)
31. Rizner TL, Lin HK, and Penning TM (2003a) Role of human type 3 3alpha-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells. Chem Biol Interact 143-144:401-409. (Pubitemid 36246454)
32. Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, and Penning TM (2003b) Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144:2922-2932. (Pubitemid 36819895)
33. Shiraishi H, Ishikura S, Matsuura K, Deyashiki Y, Ninomiya M, Sakai S, and Hara A (1998) Sequence of the cDNA of a human dihydrodiol dehydrogenase isoform (AKR1C2) and tissue distribution of its mRNA. Biochem J 334:399-405. (Pubitemid 28448583)
34. Soronen P, Laiti M, Törn S, Härkönen P, Patrikainen L, Li Y, Pulkka A, Kurkela R, Herrala A, Kaija H, et al. (2004) Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 92:281-286. (Pubitemid 40128249)
35. Suzuki K, Nishiyama T, Hara N, Yamana K, Takahashi K, and Labrie F (2007) Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis 10:301-306. (Pubitemid 47351410)
36. Swanson C, Mellström D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, Karlsson M, Ljunggren O, Smith U, Eriksson AL, et al. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab 92:4878-4882. (Pubitemid 350223472)
37. Yee DJ, Balsanek V, Bauman DR, Penning TM, and Sames D (2006) Fluorogenic metabolic probes for direct activity readout of redox enzymes: selective measurement of human AKR1C2 in living cells. Proc Natl Acad Sci U S A 103:13304-13309. (Pubitemid 44380103)